CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
CMP-001-010 is a Phase 2 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV)
administered to participants with refractory unresectable or metastatic melanoma.
The primary objective of the study is to determine confirmed objective response with CMP-001
in combination with nivolumab in subjects with refractory unresectable or metastatic
melanoma.
The secondary objectives are to:
- To evaluate the safety and tolerability of CMP-001 administered by intratumoral (IT)
injection in combination with nivolumab in subjects with refractory unresectable or
metastatic melanoma.
- To evaluate the efficacy of CMP-001 in combination with nivolumab in subjects with
refractory unresectable or metastatic melanoma.
- To assess the pharmacokinetic (PK) profile of CMP-001 in combination with nivolumab in
subjects with refractory unresectable or metastatic melanoma.
- To assess and describe the immunogenicity of CMP-001 in combination with nivolumab in
subjects with refractory unresectable or metastatic melanoma.